101 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
million in the same period of 2023.
R&D Expenses: Research and development expenses were $71.7 million, including $5.0 million of non-cash stock … , net
Collaboration revenue - related party
Total revenue
Operating costs and expenses:
Cost of revenues
Research and development
selling, general
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
in the same period of 2022.
R&D Expenses: Research and development expenses were $64.3 million, including $4.7 million of non-cash stock-based compensation … revenue
Total revenue
Operating costs and expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Restructuring
424B5
6m7bkqgs6
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-99.1
wvs abnoy
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
niefbh
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
ftol0imf g7aoh624
2 May 23
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
zcwzpa8 p755k
6 Dec 22
Other Events
6:51am
8-K
EX-99.1
d5uptg
8 Nov 22
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
6:45am